Compare Biogen Inc (BIIB) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kaltura Inc — how do they compare? Biogen Inc trades at $205.26 (market cap $30.13B), while Kaltura Inc trades at $1.59 (market cap $249.42M). The key difference: Biogen Inc is far larger — about 120.8× Kaltura Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | KLTR | |
|---|---|---|
Market Cap | $30.13B | $249.42M |
Sector | Health | Technology |
52-Week High | $216.63 | $1.89 |
52-Week Low | $128.93 | $1.08 |
Enterprise Value | $37.20B | $261.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Kaltura (KLTR) trades at $1.61, down 1.83% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported Q2 2026 earnings that beat expectations, with revenue stable around $181 million and improving net loss margins. Recent news highlights leadership in virtual event platforms and AI technology awards, alongside significant insider selling in August 2026.
The outlook is mixed: analyst consensus leans buy (44.45%) with strong gross margins (72.05%), but persistent net losses and high valuation ratios (EV/EBITDA 336.29) pose risks. Investment opportunity hinges on AI product growth and cost management, while execution risks and cash flow volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
